Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.

ABSTRACT:

Objective

In a randomized multi-center trial, we demonstrated that inhaled nitric oxide begun between 7 and 21 days and given for 24 days significantly increased survival without bronchopulmonary dysplasia (BPD) in ventilated premature infants weighing <1250 g. Because some preventative BPD treatments are associated with neurodevelopmental impairment, we designed a follow-up study to assess the safety of nitric oxide.

Study design

Our hypothesis was that inhaled nitric oxide would not increase neurodevelopmental impairment compared with placebo. We prospectively evaluated neurodevelopmental and growth outcomes at 24 months postmenstrual age in 477 of 535 surviving infants (89%) enrolled in the trial.

Results

In the treated group, 109 of 243 children (45%) had neurodev

SUBMITTER: Walsh MC 

PROVIDER: S-EPMC2843768 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature